Loading
A phase 2 trial of DISC-3405 in myeloproliferative neoplasms, run by Disc Medicine, Inc, active and no longer recruiting.
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) is a phase 2 interventional study registered as NCT06985147 by Disc Medicine, Inc, with 60 participants enrolled, started 2025-08-12 and due to reach its primary completion in 2027-02. Interventions recorded: DISC-3405.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Disc Medicine, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/